Related Experiment Video
Updated: May 9, 2025
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC
Xin Xing1,2, Shi-Qi Yin1, Xia-Qing Li1
1Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China.
Background:
Immune evasion is a crucial event in the progression of pancreatic ductal adenocarcinoma (PDAC). The identification of new immunotherapeutic targets may provide a promising platform for advancing PDAC treatment. This study aims to investigate the role of beta-1,4-galactosyltransferase-5 (B4GALT5) in immune evasion by pancreatic cancer cells and evaluate its potential as an immunotherapeutic target.
Methods:
We conducted a comprehensive analysis using RNA sequencing data and tissue microarrays from patients with PDAC to investigate the association between B4GALT5 expression and patient prognosis. Using animal models, we further explored the impact of B4GALT5 on the quantity and activity of tumor-infiltrating CD8+ T cells. RNA sequencing and co-immunoprecipitation were used to explore the mechanism by which B4GALT5 regulates major histocompatibility complex (MHC-I) levels.
Results:
Our study demonstrates that high expression of B4GALT5 in tumor cells is significantly associated with poor prognosis in patients with PDAC and reduced cytotoxic activity of tumor-infiltrating CD8+ T cells. Specifically, B4GALT5 suppresses MHC-I expression in tumor cells through the endoplasmic reticulum-associated degradation pathway, enabling them to evade immune surveillance by CD8+ T cells.
Conclusions:
B4GALT5 impairs CD8+ T-cell recognition of tumor cells by regulating MHC-I levels, thereby promoting immune evasion. This makes B4GALT5 a highly promising immunotherapeutic target for improving the poor prognosis of patients with PDAC.
Insights
Beta-1,4-galactosyltransferase-5 (B4GALT5) promotes pancreatic cancer immune evasion by reducing CD8+ T cell activity. Targeting B4GALT5 offers a promising strategy to improve outcomes for pancreatic ductal adenocarcinoma patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immune evasion is critical in pancreatic ductal adenocarcinoma (PDAC) progression.
- Identifying novel immunotherapeutic targets is key for advancing PDAC treatment.
- Beta-1,4-galactosyltransferase-5 (B4GALT5) is investigated for its role in immune evasion.
Purpose of the Study:
- To investigate the role of B4GALT5 in pancreatic cancer immune evasion.
- To evaluate B4GALT5 as a potential immunotherapeutic target for PDAC.
Main Methods:
- Analysis of RNA sequencing data and tissue microarrays from PDAC patients.
- Assessment of B4GALT5 impact on tumor-infiltrating CD8+ T cells in animal models.
- Exploration of B4GALT5 mechanism regulating Major Histocompatibility Complex (MHC-I) levels via RNA sequencing and co-immunoprecipitation.
Main Results:
- High B4GALT5 expression correlates with poor PDAC prognosis and reduced CD8+ T cell cytotoxic activity.
- B4GALT5 suppresses tumor cell MHC-I expression through the endoplasmic reticulum-associated degradation pathway.
- Tumor cells evade CD8+ T cell immune surveillance by downregulating MHC-I via B4GALT5.
Conclusions:
- B4GALT5 hinders CD8+ T cell recognition of tumor cells by modulating MHC-I levels, promoting immune evasion.
- B4GALT5 is a promising immunotherapeutic target for improving PDAC patient prognosis.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...